HK1168146A1 - Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction - Google Patents

Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction

Info

Publication number
HK1168146A1
HK1168146A1 HK12108726.0A HK12108726A HK1168146A1 HK 1168146 A1 HK1168146 A1 HK 1168146A1 HK 12108726 A HK12108726 A HK 12108726A HK 1168146 A1 HK1168146 A1 HK 1168146A1
Authority
HK
Hong Kong
Prior art keywords
patients suffering
diseases related
endothelial function
based stratification
vasoactive hormone
Prior art date
Application number
HK12108726.0A
Other languages
English (en)
Chinese (zh)
Inventor
Andreas Bergmann
Joachim Struck
Oliver Hartmann
Leong Loke Ng
Original Assignee
有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 有限公司 filed Critical 有限公司
Publication of HK1168146A1 publication Critical patent/HK1168146A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12108726.0A 2009-05-05 2012-09-06 Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction HK1168146A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09159472 2009-05-05
EP09163269 2009-06-19
EP09016143 2009-12-30
PCT/EP2010/056081 WO2010128071A1 (fr) 2009-05-05 2010-05-05 Stratification à base d'hormone vasoactive de patients souffrant de maladies liées à la fonction ou à un dysfonctionnement endothélial

Publications (1)

Publication Number Publication Date
HK1168146A1 true HK1168146A1 (en) 2012-12-21

Family

ID=42224880

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12108726.0A HK1168146A1 (en) 2009-05-05 2012-09-06 Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction

Country Status (8)

Country Link
US (1) US9229013B2 (fr)
EP (1) EP2427764B1 (fr)
JP (1) JP5753159B2 (fr)
CN (1) CN102428368B (fr)
DK (1) DK2427764T3 (fr)
ES (1) ES2643033T3 (fr)
HK (1) HK1168146A1 (fr)
WO (1) WO2010128071A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
CN103308673B (zh) * 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
EP2657707A1 (fr) * 2012-04-26 2013-10-30 B.R.A.H.M.S GmbH Biomarqueurs pour le diagnostic, le pronostic, l'évaluation et la syncope de stratification de thérapie
WO2014053502A1 (fr) * 2012-10-02 2014-04-10 Sphingotec Gmbh Méthode permettant de prédire le risque d'apparition d'un cancer ou de diagnostiquer un cancer chez un sujet féminin
EP2943792B1 (fr) * 2013-01-08 2018-11-14 SphingoTec GmbH Procédé de prédiction du risque qu'un sujet développe un cancer ou de diagnostic du cancer chez un sujet
EP3024847A1 (fr) * 2013-07-25 2016-06-01 Novartis AG Polypeptides cyclique disulfure pour le traitement de l'insuffisance cardiaque
CN105612173A (zh) * 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状apelin衍生物
WO2015049243A1 (fr) * 2013-10-01 2015-04-09 Sphingotec Gmbh Méthode de prédiction du risque de survenue d'un événement cardiaque indésirable majeur
AU2015242354A1 (en) * 2014-04-03 2016-11-10 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure
CA2889826A1 (fr) * 2014-06-20 2015-12-20 Emmanuel E. Egom Methodes de traitement de l'hypertension pulmonaire par administration d'un recepteur du peptide natriuretique c signalant des activateurs de sequence
WO2017089474A1 (fr) * 2015-11-27 2017-06-01 Brahms Gmbh Mr-proadm utilisé comme marqueur pour l'état de volume extracellulaire d'un sujet
AU2017246588A1 (en) * 2016-04-08 2018-09-27 Centre National De La Recherche Scientifique - Cnrs - Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
ES2948446T3 (es) * 2016-07-08 2023-09-12 Sphingotec Gmbh Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda
US20200182885A1 (en) * 2017-05-30 2020-06-11 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion
EP3438668A1 (fr) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnostic et stratification des risques d'infections fongiques
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP3682236A1 (fr) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Proadrénomédulline en tant qu'indicateur pour thérapie de remplacement rénal chez des patients gravement malades
EP3682245A1 (fr) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Utilisation de proadm en tant que marqueur de surveillance thérapeutique pour des patients en phase critique
JP7346389B2 (ja) * 2017-09-13 2023-09-19 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 異常な血小板レベルのマーカーとしてのプロアドレノメジュリン
CN109283341A (zh) * 2018-10-17 2019-01-29 北京市心肺血管疾病研究所 一组预测心肌梗死患者的pci术后预后的生物标志物
CN109799338B (zh) * 2019-01-14 2022-02-11 湖南达道生物工程有限公司 一种适用于末梢血免疫层析定量检测的试纸及其应用
EP4023218A1 (fr) * 2020-12-02 2022-07-06 S-Form Pharma Thérapie combinée pour les patients souffrant d'une dyspnée aiguë et/ou persistante

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
WO2008049422A2 (fr) * 2006-10-26 2008-05-02 Brahms Aktiengesellschaft Stratification des risques du syndrome coronarien aigu au moyen de fragments et de peptides partiels de la provasopressine, en particulier de la copeptine ou de la neurophysine ii
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102006060835A1 (de) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2020603A1 (fr) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Procédé de stratification du risque chez des patients ayant une maladie associeé avec des coronaropathies

Also Published As

Publication number Publication date
CN102428368A (zh) 2012-04-25
EP2427764A1 (fr) 2012-03-14
JP2012526271A (ja) 2012-10-25
US9229013B2 (en) 2016-01-05
DK2427764T3 (en) 2017-09-11
EP2427764B1 (fr) 2017-07-26
US20120142120A1 (en) 2012-06-07
JP5753159B2 (ja) 2015-07-22
WO2010128071A1 (fr) 2010-11-11
ES2643033T3 (es) 2017-11-21
CN102428368B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
HK1168146A1 (en) Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction
EP2480576A4 (fr) Antagonistes de pcsk9
EP2438246A4 (fr) Aspects de construction
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
EP2455452A4 (fr) Cellule souche pluripotente isolée à partir de tissue organique
HK1200750A1 (en) Methods of reduction of interpatient variability
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
EP2499255A4 (fr) Production efficace de peptides
IL219901A0 (en) Pharmaceutical composiitons for the stimulation of stem cells
IL216612A0 (en) Inhhibition of inflammation using antagonists of muc1
PL2401244T3 (pl) Sposoby produkcji ceramicznych struktur
EP2418188A4 (fr) Corps de mortier de ciment
EP2519537A4 (fr) Purification des protéines
GB2469543B (en) Construction of geometrical shapes
GB0905189D0 (en) Improvements relating to crutches
EP2478010A4 (fr) Peptide partiel de lacritine
HU0900712D0 (en) New methods and intermediers for the synthesis of ace-inhibitor
TWM363914U (en) Improved structure of medicine case
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
GB201016243D0 (en) Columbarium
TWM386109U (en) Improved structure of water dispenser
TWM365694U (en) Improved structure of bowl
TWM390140U (en) Improved structure of walker
TWM372150U (en) Structure improvement of ingot